Therapeutic plasma exchange in the pediatric intensive care unit: a single-center retrospective study.
10.7499/j.issn.1008-8830.2204172
- Author:
Jian-She CAO
1
;
Jie HE
1
;
Xin-Ping ZHANG
1
;
Xiong ZHOU
1
;
Zheng-Hui XIAO
1
Author Information
1. Pediatric Intensive Care Unit, Hunan Children's Hospital, Changsha 410007, China.
- Publication Type:Journal Article
- Keywords:
Child;
Complication;
Indication;
Therapeutic plasma exchange
- MeSH:
Child;
Humans;
United States;
Plasma Exchange/adverse effects*;
Retrospective Studies;
Intensive Care Units, Pediatric;
Sepsis/etiology*;
Hematologic Diseases/therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(10):1149-1153
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the indication for therapeutic plasma exchange (TPE) and related complications in children admitted to the pediatric intensive care unit.
METHODS:A retrospective analysis was performed on the medical records of the children who received TPE in the Pediatric Intensive Care Unit, Hunan Children's Hospital, from March 2015 to March 2021. The indication for TPE and related complications were analyzed and compared with the American Society for Apheresis (ASFA) indication categories.
RESULTS:A total of 405 TPE treatment sessions were performed for 196 children, among whom 76 children (38.8%) also received continuous renal replacement therapy and 147 children (75.0%) survived. The children with neurological diseases had the highest survival rate of 93.1% (27/29). The top three indications for TPE were hematologic diseases (61/196, 31.1%), sepsis with multiple organ dysfunction (41/196, 20.9%), and liver diseases (36/196, 18.4%). The children with hematologic diseases received the highest number of 129 TPE treatment sessions. The subjects with ASFA category Ⅲ indications accounted for the highest proportion of 76.5% (150/196), followed by those with ASFA category Ⅰ indications (11.2%, 22/196), ASFA category Ⅱ indications (7.1%, 14/196), and unknown category (5.1%, 10/196), and no ASFA category Ⅳ indications were observed. The incidence rate of TPE complications was 12.3% (50/405), and the most common complications were pipeline coagulation (4.2%, 17/405) and hypotension (3.7%, 15/405). No serious adverse events were observed.
CONCLUSIONS:TPE can be safely used for the treatment of critically ill children with indications in an experienced pediatric intensive care unit.
